ChinaBio® Today Articles

Welcome to the ChinaBio® Today store. As a service to our readers, we offer access to individual articles for only $5.00 (USD) each.  Of course, a subscription is only $20/mo, so you may prefer to subscribe.  If so, click on Subscribe in the menu.

Browse


All Products

Viewing 391 - 405 of 5738 products
Innovent Starts China Phase III Trial for Dual Agonist Diabetes Therapy
$5.00
Available
Immune-Onc Adds $25 Million to B Round for Novel Myeloid Checkpoint Inhibitors
$5.00
Available
Duality Licenses ADC Platform to Adcendo for Mesenchymal Cancer Program
$5.00
Available
WuXi Biologics Signs $1.5 Billion Pact with GSK for Four Novel TCE Antibodies
$5.00
Available
HighTide Closes $107 Million Round for Metabolic/Digestive Disease Candidates
$5.00
Available
ArriVent in Hunt for $145 Million to Finance US In-licensing Operations
$5.00
Available
Transcenta Approved to Start China Trials of Gremlin1 mAb for Prostate Cancer
$5.00
Available
Biocytogen Out-Licenses Global Rights for mAb Candidates to Hansoh
$5.00
Available
ProfoundBio Starts US Trial of ADC in Solid Tumor Cancers
$5.00
Available
Boan Stages $20 Million Hong Kong IPO for Biosimilar/Novel mAb Drugs
$5.00
Available
InnoCare Approved to Launch Cytolytic CD-19 Immunotherapy in Hong Kong
$5.00
Available
Everest Starts Operations in New mRNA Vaccine Production Facility
$5.00
Available
Ablaze Pharma Forms CDMO Partnership with Yonghe for Radiopharmaceuticals
$5.00
Available
Junshi Out-licenses Middle East/North African Rights for PD-1 to Hikma Pharma
$5.00
Available
WuXi XDC to Offer GeneQuantum’s Platforms for Bioconjugate Development
$5.00
Available